GLP-1 wars: Lilly's FDA-approved oral weight-loss pill puts Novo Nordisk's Wegovy franchise under fresh pressure

Foundayo launches on April 6 at the same price as Novo's pill, threatening to reshape the $50 billion obesity drug market before Novo's first-quarter...